Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Sep;72(3):691–695. doi: 10.1038/bjc.1995.395

Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression.

M Mandai 1, I Konishi 1, T Komatsu 1, T Mori 1, S Arao 1, H Nomura 1, Y Kanda 1, H Hiai 1, M Fukumoto 1
PMCID: PMC2033876  PMID: 7669582

Abstract

Alteration of expression levels of the nm23 genes has previously been correlated with metastatic status of ovarian epithelial carcinoma. To elucidate the relevance of the qualitative changes of the nm23 genes to progression of ovarian carcinoma and/or to nm23 expression levels of the tumour, 41 samples of epithelial ovarian tumours [three benign, three low malignant potential (LMP), and 35 frankly malignant tumours] were studied for mutation of the nm23-H1 and the nm23-H2 genes using single-strand conformational polymorphism (SSCP) analysis. In addition, loss of heterozygosity (LOH) at the nm23 locus on chromosome 17q was studied by CA repeat polymorphism analysis. Mutation of the K-ras gene was also analysed in the same specimens. A novel mutation of the nm23 gene was found in one case of stage III serous carcinoma without lymph model metastases. Sequencing of the subcloned mutant cDNA revealed a missense mutation from TGG to CGG at codon 133 of the nm23-H2 gene, resulting in a change from Trp to Arg. LOH at the nm23 locus was detected in 5 of 23 (21.7%) informative cases of ovarian carcinoma. Mutation of the K-ras gene was detected in 2 of 35 (5.7%) carcinomas at codons 12 and 13 respectively. There was no correlation between clinical stage or metastatic status of ovarian carcinoma and nm23 mutation, LOH at the nm23 locus or K-ras mutation. The expression levels of both the nm23-H1 and the nm23-H2 genes were lower in the tumour with nm23-H2 mutation and higher in those with K-ras mutation. This suggests that mutation of the nm23 genes and the K-ras gene affects carcinogenesis or progression of ovarian carcinoma by modulating expression of the nm23 genes.

Full text

PDF
693

Images in this article

693Figure 1
on p.693
693Figure 2
on p.693
694Figure 3
on p.694

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes R., Masood S., Barker E., Rosengard A. M., Coggin D. L., Crowell T., King C. R., Porter-Jordan K., Wargotz E. S., Liotta L. A. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol. 1991 Aug;139(2):245–250. [PMC free article] [PubMed] [Google Scholar]
  2. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990 Jul 1;50(13):4087–4091. [PubMed] [Google Scholar]
  3. Cohn K. H., Wang F. S., Desoto-LaPaix F., Solomon W. B., Patterson L. G., Arnold M. R., Weimar J., Feldman J. G., Levy A. T., Leone A. Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma. Lancet. 1991 Sep 21;338(8769):722–724. doi: 10.1016/0140-6736(91)91444-y. [DOI] [PubMed] [Google Scholar]
  4. Enomoto T., Weghorst C. M., Inoue M., Tanizawa O., Rice J. M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 1991 Oct;139(4):777–785. [PMC free article] [PubMed] [Google Scholar]
  5. Flørenes V. A., Aamdal S., Myklebost O., Maelandsmo G. M., Bruland O. S., Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992 Nov 1;52(21):6088–6091. [PubMed] [Google Scholar]
  6. Fukumoto M., Estensen R. D., Sha L., Oakley G. J., Twiggs L. B., Adcock L. L., Carson L. F., Roninson I. B. Association of Ki-ras with amplified DNA sequences, detected in human ovarian carcinomas by a modified in-gel renaturation assay. Cancer Res. 1989 Apr 1;49(7):1693–1697. [PubMed] [Google Scholar]
  7. Hailat N., Keim D. R., Melhem R. F., Zhu X. X., Eckerskorn C., Brodeur G. M., Reynolds C. P., Seeger R. C., Lottspeich F., Strahler J. R. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest. 1991 Jul;88(1):341–345. doi: 10.1172/JCI115299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hall J. M., Friedman L., Guenther C., Lee M. K., Weber J. L., Black D. M., King M. C. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet. 1992 Jun;50(6):1235–1242. [PMC free article] [PubMed] [Google Scholar]
  9. Haut M., Steeg P. S., Willson J. K., Markowitz S. D. Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential. J Natl Cancer Inst. 1991 May 15;83(10):712–716. doi: 10.1093/jnci/83.10.712. [DOI] [PubMed] [Google Scholar]
  10. Jacobs I. J., Smith S. A., Wiseman R. W., Futreal P. A., Harrington T., Osborne R. J., Leech V., Molyneux A., Berchuck A., Ponder B. A. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res. 1993 Mar 15;53(6):1218–1221. [PubMed] [Google Scholar]
  11. Koshiyama M., Konishi I., Mandai M., Komatsu T., Yamamoto S., Nanbu K., Mori T. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status. Virchows Arch. 1995;425(6):603–609. doi: 10.1007/BF00199350. [DOI] [PubMed] [Google Scholar]
  12. Lascu I., Chaffotte A., Limbourg-Bouchon B., Véron M. A Pro/Ser substitution in nucleoside diphosphate kinase of Drosophila melanogaster (mutation killer of prune) affects stability but not catalytic efficiency of the enzyme. J Biol Chem. 1992 Jun 25;267(18):12775–12781. [PubMed] [Google Scholar]
  13. Leone A., Seeger R. C., Hong C. M., Hu Y. Y., Arboleda M. J., Brodeur G. M., Stram D., Slamon D. J., Steeg P. S. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993 Apr;8(4):855–865. [PubMed] [Google Scholar]
  14. MacDonald N. J., De la Rosa A., Benedict M. A., Freije J. M., Krutsch H., Steeg P. S. A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential. J Biol Chem. 1993 Dec 5;268(34):25780–25789. [PubMed] [Google Scholar]
  15. Mandai M., Konishi I., Koshiyama M., Mori T., Arao S., Tashiro H., Okamura H., Nomura H., Hiai H., Fukumoto M. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994 Apr 1;54(7):1825–1830. [PubMed] [Google Scholar]
  16. Moréra S., Lascu I., Dumas C., LeBras G., Briozzo P., Véron M., Janin J. Adenosine 5'-diphosphate binding and the active site of nucleoside diphosphate kinase. Biochemistry. 1994 Jan 18;33(2):459–467. doi: 10.1021/bi00168a010. [DOI] [PubMed] [Google Scholar]
  17. Nakayama H., Yasui W., Yokozaki H., Tahara E. Reduced expression of nm23 is associated with metastasis of human gastric carcinomas. Jpn J Cancer Res. 1993 Feb;84(2):184–190. doi: 10.1111/j.1349-7006.1993.tb02853.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nakayama T., Ohtsuru A., Nakao K., Shima M., Nakata K., Watanabe K., Ishii N., Kimura N., Nagataki S. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst. 1992 Sep 2;84(17):1349–1354. doi: 10.1093/jnci/84.17.1349. [DOI] [PubMed] [Google Scholar]
  19. Okamoto A., Sameshima Y., Yokoyama S., Terashima Y., Sugimura T., Terada M., Yokota J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res. 1991 Oct 1;51(19):5171–5176. [PubMed] [Google Scholar]
  20. Phillips N., Ziegler M., Saha B., Xynos F. Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer. 1993 Apr 22;54(1):85–91. doi: 10.1002/ijc.2910540115. [DOI] [PubMed] [Google Scholar]
  21. Sato T., Saito H., Morita R., Koi S., Lee J. H., Nakamura Y. Allelotype of human ovarian cancer. Cancer Res. 1991 Oct 1;51(19):5118–5122. [PubMed] [Google Scholar]
  22. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  23. Stahl J. A., Leone A., Rosengard A. M., Porter L., King C. R., Steeg P. S. Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991 Jan 1;51(1):445–449. [PubMed] [Google Scholar]
  24. Steeg P. S., Bevilacqua G., Kopper L., Thorgeirsson U. P., Talmadge J. E., Liotta L. A., Sobel M. E. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988 Apr 6;80(3):200–204. doi: 10.1093/jnci/80.3.200. [DOI] [PubMed] [Google Scholar]
  25. Tashiro H., Miyazaki K., Okamura H., Iwai A., Fukumoto M. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer. 1992 Mar 12;50(5):828–833. doi: 10.1002/ijc.2910500528. [DOI] [PubMed] [Google Scholar]
  26. Teng D. H., Engele C. M., Venkatesh T. R. A product of the prune locus of Drosophila is similar to mammalian GTPase-activating protein. Nature. 1991 Oct 3;353(6343):437–440. doi: 10.1038/353437a0. [DOI] [PubMed] [Google Scholar]
  27. Wang L., Patel U., Ghosh L., Chen H. C., Banerjee S. Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer Res. 1993 Feb 15;53(4):717–720. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES